Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
7.23
+0.37 (5.39%)
At close: Apr 17, 2025, 4:00 PM
7.35
+0.12 (1.66%)
Pre-market: Apr 21, 2025, 8:57 AM EDT
Intellia Therapeutics Employees
Intellia Therapeutics had 403 employees as of December 31, 2024. The number of employees decreased by 123 or -23.38% compared to the previous year.
Employees
403
Change (1Y)
-123
Growth (1Y)
-23.38%
Revenue / Employee
$143,615
Profits / Employee
-$1,287,893
Market Cap
748.43M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
NTLA News
- 6 days ago - Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA - PRNewsWire
- 10 days ago - SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - PRNewsWire
- 11 days ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - GlobeNewsWire
- 17 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLA - GlobeNewsWire
- 18 days ago - Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy - GlobeNewsWire
- 24 days ago - Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication - Seeking Alpha
- 26 days ago - Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy - GlobeNewsWire
- 5 weeks ago - Intellia Therapeutics, Inc. (NTLA) Barclays 27th Annual Global Healthcare Conference (Transcript) - Seeking Alpha